Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study

Key Result

The two-dose inactivated EV71 vaccine provides durable protection exceeding 72% against hand, foot, and mouth disease for at least 20 years in children.

Key Points

• This research aims to evaluate the long-term effectiveness of the inactivated enterovirus type 71 vaccine against hand, foot, and mouth disease in children.
• Modelled the effectiveness of a two-dose regimen of the inactivated EV71 vaccine.
• Assessed the protective duration of the vaccine.
• Analyzed protection rates under current epidemic conditions.
• The two-dose vaccination provides over 72% protection for at least 20 years.
• The model indicates sustained efficacy in the population affected by the EV71 epidemic.